Chronic Inflammatory Disease
6
2
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
16.7%
1 terminated out of 6 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Deployment o the Multidisciplinary Prospective Cohort Imminent
Chronic Inflammatory Rheumatism: Management of Comorbidities in Ambulatory Medicine
Impact of the Therapeutic Education Program "living with a Chronic Inflammatory Disease Under Biotherapy" on Patient Compliance and Quality of Life
Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers
Infusion Related Reactions in Patients Receiving Infliximab
Skin Adverse Reactions Occuring in Children Treated by Biotherapy for Chronic Inflammatory Disease